Tirzepatide

Tirzepatide Research Peptide

Tirzepatide is a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist that has become an important compound in metabolic, endocrine and peptide-receptor research.

By activating both GIP and GLP-1 receptors, Tirzepatide provides researchers with an experimental model for investigating interconnected pathways involved in glucose regulation, appetite, caloric intake and energy metabolism.

Pure Axis Peptides offers Tirzepatide as a research-use material for qualified laboratory and scientific investigations.

What Is Tirzepatide?

Tirzepatide is a synthetic peptide engineered to activate both the GIP receptor and GLP-1 receptor. Its structure includes a fatty diacid side chain that promotes albumin binding and contributes to its prolonged pharmacokinetic profile.

The dual-receptor mechanism distinguishes Tirzepatide from conventional compounds that selectively target only the GLP-1 receptor.

This makes Tirzepatide particularly relevant to research investigating how GIP and GLP-1 signaling interact within metabolic and endocrine systems.

Tirzepatide and GIP/GLP-1 Receptor Signaling

GIP and GLP-1 are incretin hormones involved in nutrient-responsive metabolic signaling.

Research into Tirzepatide focuses on the combined activation of these receptor pathways and their downstream effects on:

• Glucose-dependent insulin secretion
• Glucagon regulation
• Appetite signaling
• Caloric intake
• Energy balance
• Metabolic homeostasis
• Pancreatic endocrine signaling
• Gastrointestinal physiology
• Neural pathways involved in feeding

FDA pharmacology information describes Tirzepatide as selectively activating both GIP and GLP-1 receptors. Nonclinical research also indicates that both receptor systems are represented in brain regions involved in appetite and food-intake regulation.

Tirzepatide and Metabolic Research

Tirzepatide is widely studied as a model for multi-receptor metabolic signaling.

Experimental and clinical research has investigated how simultaneous GIP and GLP-1 receptor activation affects body weight, glucose metabolism and cardiometabolic parameters.

In the 72-week SURMOUNT-1 Phase 3 trial, Tirzepatide produced substantial and sustained reductions in body weight in adults with obesity or overweight with weight-related complications. Gastrointestinal adverse events were the most frequently reported adverse events and occurred primarily during dose escalation.

For laboratory researchers, these findings provide useful context for investigating the biological consequences of dual incretin receptor activation.

Tirzepatide and Glucose Regulation

GLP-1 and GIP receptor signaling both participate in pancreatic endocrine regulation.

Tirzepatide stimulates glucose-dependent insulin secretion and reduces glucagon secretion, providing researchers with an experimental compound for studying the relationship between incretin signaling and glucose homeostasis.

Research applications can include:

Incretin Biology: Investigating GIP and GLP-1 receptor activation.

Endocrine Research: Studying pancreatic hormone signaling and glucose-dependent insulin secretion.

Metabolic Research: Examining pathways involved in glucose and energy metabolism.

Neuroscience: Investigating receptor signaling in neural circuits associated with appetite and food intake.

Peptide Pharmacology: Studying the structure, stability and pharmacological properties of long-acting peptide agonists.

Tirzepatide and Appetite Research

GLP-1 and GIP receptors are present in areas of the nervous system associated with appetite regulation.

Nonclinical research indicates that Tirzepatide can activate neurons in brain regions involved in the regulation of appetite and food intake. Its effects on caloric intake are therefore an important area of metabolic-neuroscience research.

This makes Tirzepatide relevant to experimental studies investigating the relationship between incretin signaling, appetite and energy homeostasis.

Tirzepatide and Long-Acting Peptide Design

Tirzepatide incorporates a C20 fatty diacid that enables albumin binding and contributes to an extended half-life. This structural feature makes Tirzepatide useful for research into the relationship between peptide modification, receptor activity and pharmacokinetic behavior.

Researchers studying peptide engineering can therefore investigate Tirzepatide alongside other long-acting peptide molecules to examine how structural modifications influence biological persistence.

Tirzepatide Research Applications

Tirzepatide may be relevant to laboratory studies involving:

• GIP receptor research
• GLP-1 receptor research
• Dual incretin agonists
• Incretin signaling
• Glucose metabolism
• Insulin signaling
• Glucagon regulation
• Appetite and food-intake pathways
• Energy homeostasis
• Metabolic neuroscience
• Endocrine research
• Peptide pharmacology
• Long-acting peptide design
• Receptor structure-function research

Tirzepatide and Related Metabolic Peptides

Tirzepatide fits naturally into a broader metabolic research cluster alongside other incretin and metabolic peptides.

Researchers can explore the GLP-1 & Metabolic Peptides collection for related compounds.

For comparison with a selective GLP-1 receptor agonist, see Semaglutide.

Researchers interested in next-generation multi-receptor agonists can also explore Retatrutide, which targets GIP, GLP-1 and glucagon receptors.

For an amylin-based metabolic research compound, see Cagrilintide.

Explore the wider Peptides collection or Research Chemicals collection for additional laboratory materials.

Research Use Only

Tirzepatide supplied by Pure Axis Peptides is intended strictly for laboratory and scientific research. It is not intended for human consumption, self-administration, diagnosis, treatment, cure, or prevention of any disease or medical condition. The availability of an approved pharmaceutical formulation does not make a research-material product equivalent to an approved medicinal product. Researchers should evaluate all materials according to their experimental requirements, product documentation and applicable laboratory procedures.

Internal Linking Recommendations

Primary Internal Links

• GLP-1 & Metabolic Peptides → https://pureaxispeptides.com/product-category/peptides/glp-1-metabolic/
• Semaglutide → https://pureaxispeptides.com/product/semaglutide/
• Retatrutide → https://pureaxispeptides.com/product/retatrutide/
• Cagrilintide → https://pureaxispeptides.com/product/cagrilintide/
• Peptides → https://pureaxispeptides.com/product-category/peptides/
• Research Chemicals → https://pureaxispeptides.com/product-category/research-chemicals/
• Shop All Products → https://pureaxispeptides.com/shop/

Verify the live WooCommerce URLs before publishing because product/category slugs may change.

External Scientific References

• FDA — Current Zepbound (tirzepatide) Prescribing Information:
  https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/217806s042lbl.pdf
• FDA — Tirzepatide mechanism of action:
  https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/217806Orig1s020lbl.pdf
• NEJM — SURMOUNT-1 Tirzepatide Trial:
  https://www.nejm.org/doi/10.1056/NEJMoa2206038
• NEJM — Three-year Tirzepatide data:
  https://www.nejm.org/doi/10.1056/NEJMoa2410819

Product Tags

Tirzepatide, Tirzepatide Peptide, Tirzepatide Research Peptide, Tirzepatide Research, GIP, GIP Peptide, GLP-1, GLP-1 Peptide, GIP GLP-1, GIP GLP-1 Receptor Agonist, Dual Incretin Agonist, Dual Agonist, Incretin Research, GIP Research, GLP-1 Research, Metabolic Peptide, Metabolic Research, Metabolic Research Peptide, Glucose Research, Glucose Regulation, Insulin Research, Appetite Research, Energy Balance, Endocrine Research, Peptide Pharmacology, Long-Acting Peptide, Research Peptide, Laboratory Research